Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT03580382
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.

Key Dates

Start date
Jul 6, 2018
Status verified
May 2020
Primary completion
Sep 26, 2018
Completion
Sep 26, 2018

Study Design

Enrollment
3 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NRAS mutant melanoma
    C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
  • Experimental: WT melanoma
    C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)

Primary Outcome Measure

Objective Response Rate [ Time Frame: 48 Months ]

Locations (2)

FacilityCityStateZIPSite coordinators
New York University School of MedicineNew YorkNew York10016-
Thomas Jefferson UniversityPhiladelphiaPennsylvania19107-

Find similar trials in New York, NY

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
New York University School of Medicine· New York, NYThomas Jefferson University· Philadelphia, PA

Related Studies